• Bonyf flagged recent share price moves as driven by extremely low trading volumes, citing a gap between market value and intrinsic value.
• CEO, a major shareholder, invested more than EUR 500,000, signalling confidence in the strategy and outlook.
• Three-year plan targets faster growth, stronger margins, broader global reach, led by scaling patented Periocream for dental practitioners.
• Target set for at least 15 new distribution partners by end-2026 to expand international sales.
• Automated Periocream syringe line due by end-October 2026, designed for about 2,000 syringes per hour.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bonyf NV published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.